risperidone has been researched along with Anxiety Neuroses in 28 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders." | 9.22 | Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022) |
| "In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms." | 9.20 | Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. ( Aman, MG; Arnold, LE; Bangalore, S; Brown, NV; Buchan-Page, K; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Hurt, EA; Li, X; McNamara, NK; Molina, BS; Rice, R; Rundberg-Rivera, EV, 2015) |
| "On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures." | 9.14 | Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009) |
| "Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks." | 9.12 | An open-label trial of risperidone augmentation for refractory anxiety disorders. ( Christian, KM; Fischmann, D; Hoge, EA; Kinrys, G; Pollack, MH; Simon, NM; Worthington, JJ, 2006) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 9.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders." | 5.22 | Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022) |
| "In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms." | 5.20 | Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. ( Aman, MG; Arnold, LE; Bangalore, S; Brown, NV; Buchan-Page, K; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Hurt, EA; Li, X; McNamara, NK; Molina, BS; Rice, R; Rundberg-Rivera, EV, 2015) |
| "On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures." | 5.14 | Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009) |
| "Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks." | 5.12 | An open-label trial of risperidone augmentation for refractory anxiety disorders. ( Christian, KM; Fischmann, D; Hoge, EA; Kinrys, G; Pollack, MH; Simon, NM; Worthington, JJ, 2006) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 5.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "There is some evidence that in the short term risperidone may reduce aggression and conduct problems in children and youths with disruptive behaviour disorders There is also evidence that this intervention is associated with significant weight gain." | 4.95 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2017) |
| "There is some limited evidence of efficacy of risperidone reducing aggression and conduct problems in children aged 5 to 18 with disruptive behaviour disorders in the short term." | 4.88 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2012) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| " The addition of risperidone to behavioral and psychopharmacologic treatments was observed to significantly increase oral intake and accelerate weight gain." | 3.72 | The effectiveness of risperidone in the treatment of three children with feeding disorders. ( Berger-Gross, P; Coletti, DJ; Hirschkorn, K; Simpser, EF; Terranova, E, 2004) |
| " Data were derived from an earlier study, designed to compare efficacy and tolerability of fixed dosage of extended-release venlafaxine, mitazapine, paroxetine, and risperidone, sodium valproate, buspirone, trazodone or thyroid hormone augmenting to paroxetine in those patients." | 2.78 | Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. ( Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C, 2013) |
| "Risperidone is a new efficacious antipsychotic with a low propensity for extrapyramidal side effects." | 2.70 | Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. ( Bruggeman, R; Buitelaar, JK; Gericke, GS; Hawkridge, SM; Temlett, JA; van der Linden, C, 2001) |
| "Risperidone has been shown to be a safe and effective atypical antipsychotic agent." | 2.44 | Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. ( Bradbury, C; da Silva, TL; McKay, M; Ravindran, AV, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (53.57) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Elnaiem, W | 1 |
| Benmelouka, AY | 1 |
| Elgendy, AMN | 1 |
| Abdelgalil, MS | 1 |
| Brimo Alsaman, MZ | 1 |
| Mogheeth, A | 1 |
| Ali, MM | 1 |
| Yousof, SM | 1 |
| Haddad, PM | 1 |
| Al Abdulla, M | 1 |
| Latoo, J | 1 |
| Iqbal, Y | 1 |
| Loy, JH | 2 |
| Merry, SN | 2 |
| Hetrick, SE | 2 |
| Stasiak, K | 2 |
| Wu, Z | 1 |
| Chen, J | 1 |
| Yuan, C | 1 |
| Hong, W | 1 |
| Peng, D | 1 |
| Zhang, C | 1 |
| Cao, L | 1 |
| Fang, Y | 1 |
| Hershenberg, R | 1 |
| Gros, DF | 1 |
| Brawman-Mintzer, O | 2 |
| Connolly, JG | 1 |
| Toomey, TJ | 1 |
| Schneeweiss, MC | 1 |
| Arnold, LE | 1 |
| Gadow, KD | 1 |
| Farmer, CA | 1 |
| Findling, RL | 1 |
| Bukstein, O | 1 |
| Molina, BS | 1 |
| Brown, NV | 1 |
| Li, X | 1 |
| Rundberg-Rivera, EV | 1 |
| Bangalore, S | 1 |
| Buchan-Page, K | 1 |
| Hurt, EA | 1 |
| Rice, R | 1 |
| McNamara, NK | 1 |
| Aman, MG | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Pandina, GJ | 2 |
| Revicki, DA | 1 |
| Kleinman, L | 1 |
| Turkoz, I | 2 |
| Wu, J | 1 |
| Mahmoud, R | 1 |
| Gharabawi, GM | 1 |
| Sheehan, DV | 2 |
| McElroy, SL | 2 |
| Harnett-Sheehan, K | 1 |
| Keck, PE | 1 |
| Janavs, J | 1 |
| Rogers, J | 1 |
| Gonzalez, R | 1 |
| Shivakumar, G | 1 |
| Suppes, T | 2 |
| Moncrieff, J | 1 |
| Cohen, D | 1 |
| Mason, JP | 1 |
| Parikh, SV | 1 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Lorenz, RA | 1 |
| Jackson, CW | 1 |
| Saitz, M | 1 |
| Depping, AM | 1 |
| Komossa, K | 1 |
| Kissling, W | 1 |
| Leucht, S | 1 |
| Seo, JS | 1 |
| Jamieson, K | 1 |
| Cosgrove, V | 1 |
| Gwizdowski, IS | 1 |
| Yang, H | 1 |
| Berger-Gross, P | 1 |
| Coletti, DJ | 1 |
| Hirschkorn, K | 1 |
| Terranova, E | 1 |
| Simpser, EF | 1 |
| Galynker, I | 1 |
| Khan, A | 1 |
| Grebchenko, Y | 1 |
| Ten, A | 1 |
| Malaya, L | 1 |
| Yanowitch, P | 1 |
| Cohen, LJ | 1 |
| Knapp, RG | 1 |
| Nietert, PJ | 1 |
| Simon, NM | 1 |
| Hoge, EA | 1 |
| Fischmann, D | 1 |
| Worthington, JJ | 1 |
| Christian, KM | 1 |
| Kinrys, G | 1 |
| Pollack, MH | 1 |
| Suh, GH | 1 |
| Greenspan, AJ | 1 |
| Choi, SK | 1 |
| Kopecek, M | 1 |
| Mohr, P | 1 |
| Novak, T | 1 |
| Gabriel, A | 1 |
| Ravindran, AV | 1 |
| Bradbury, C | 1 |
| McKay, M | 1 |
| da Silva, TL | 1 |
| Canuso, CM | 1 |
| Kujawa, M | 1 |
| Mahmoud, RA | 1 |
| Katzman, MA | 1 |
| Vermani, M | 1 |
| Jacobs, L | 1 |
| Marcus, M | 1 |
| Kong, B | 1 |
| Lessard, S | 1 |
| Galarraga, W | 1 |
| Struzik, L | 1 |
| Gendron, A | 1 |
| Kaplan, M | 1 |
| Bruggeman, R | 1 |
| van der Linden, C | 1 |
| Buitelaar, JK | 1 |
| Gericke, GS | 1 |
| Hawkridge, SM | 1 |
| Temlett, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stimulant and Risperidone in Children With Severe Physical Aggression[NCT00796302] | Phase 4 | 168 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder[NCT00277654] | Phase 3 | 111 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy[NCT00086112] | Phase 3 | 301 participants (Actual) | Interventional | Completed | |||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Behavioral Therapy for Children and Adolescents With Tourette Syndrome: A Randomized Controlled Trial in Taiwan[NCT03621059] | 46 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Antisocial Behavior Scale (ABS) is a 28-item scale that contains 10 Proactive Aggression items and six Reactive Aggression items. Each item is rated on a 3-point scale, ranging from 1 (Never) to 3 (Very often). Thus, scores on the Reactive Aggression subscale can range from 6 through 18; with higher scores indicating more reactive aggression. (NCT00796302)
Timeframe: Measured at baseline and Week 9
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 15.5 | 11.0 |
| Basic (Stimulant + PMT + Placebo) | 15.9 | 12.3 |
"Using this clinician rating scale the patient's improvement is scored on a 7-point scale which ranges from very much improved (1), through no change (4), to very much worse (7). This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Improvement scores are reported below." (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | ||
|---|---|---|---|
| Much or very much improved at endpoint | Minimally improved at endpoint | Unchanged or worse at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 63 | 11 | 6 |
| Basic (Stimulant + PMT + Placebo) | 58 | 22 | 3 |
Using this clinician rating scale the severity of the illness is scored from 1= normal to 7= extremely ill. This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Severity of Illness scores are reported below. (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | |
|---|---|---|
| Normal/Borderline/Mildly ill at endpoint | Moderately/Markedly/Severely ill at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 56 | 22 |
| Basic (Stimulant + PMT + Placebo) | 49 | 34 |
"Parent ratings of aggression and hostility on the Nisonger Child Behavior Rating Form-Typical IQ (NCBRF-TIQ) D-Total Score. The NCBRF provides 1 prosocial subscale (Positive/Social) and 6 problem behavior subscales (Conduct Problem, Oppositional Behavior, Hyperactive, Inattentive, Overly Sensitive, and Withdrawn/Dysphoric). The NCBRF has excellent internal consistency, distinguishes between controls and subjects with DBDs. Conduct Problem and Oppositional Behavior subscales map closely to DSM-IV-TR symptoms of CD and ODD; they were scored together to form a variable called the D-Total.~For the NCBRF D-Total, higher scores reflect worse behavior. Each subscale is scored by taking the rating (0 [did not occur or was not a problem] to 3 [occurred a lot or was a very severe problem]) for all component items. The D-Total score was computed by adding the 6 scores from the Oppositional subscale and the 10 items from the Conduct Problem subscale. Thus D-Total scores could range from 0-69." (NCT00796302)
Timeframe: Measured at baseline and Weeks 3, 4, 5, 6, 7, 8, 9
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 42.1 | 25.9 | 17.1 | 12.1 | 13.8 | 13.0 | 11.7 | 10.7 |
| Basic (Stimulant + PMT + Placebo) | 43.5 | 24.9 | 22.4 | 20.1 | 20.7 | 16.8 | 17.8 | 17.8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
7 reviews available for risperidone and Anxiety Neuroses
| Article | Year |
|---|---|
Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis.
Topics: Anxiety Disorders; Autism Spectrum Disorder; Child; Excitatory Amino Acid Antagonists; Humans; Meman | 2022 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2017 |
Role of atypical antipsychotics in the treatment of generalized anxiety disorder.
Topics: Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Di | 2014 |
Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
Topics: Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Di | 2010 |
Second-generation antipsychotics for anxiety disorders.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Dibenzothiazepines; H | 2010 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2012 |
Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders.
Topics: Animals; Anxiety Disorders; Depressive Disorder; Humans; Mental Disorders; Risperidone | 2007 |
9 trials available for risperidone and Anxiety Neuroses
| Article | Year |
|---|---|
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cy | 2013 |
Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
Topics: Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anxiety; Anxiety Disorders; Bipolar Disorder; Comorbi | 2009 |
Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Double-Blind Method; Female; Human | 2013 |
Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; Dose-Response Relationship, Drug; Doub | 2005 |
An open-label trial of risperidone augmentation for refractory anxiety disorders.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepi | 2006 |
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety Disorders; Cross-Over Studies; Dementia; Doub | 2006 |
Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Anxiety Disorders; Double-Blind Method; Female; Human | 2007 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
12 other studies available for risperidone and Anxiety Neuroses
| Article | Year |
|---|---|
Brief psychotic disorder associated with quarantine and mild COVID-19.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; COVID-19; Humans; Lorazepam; Ma | 2020 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; B | 2015 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Clinical Trials as Topic; Female; Humans; Male; Middle A | 2008 |
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.
Topics: Adult; Affect; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Attitude to Health; | 2009 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
The effectiveness of risperidone in the treatment of three children with feeding disorders.
Topics: Antipsychotic Agents; Anxiety Disorders; Child; Child Behavior Disorders; Feeding and Eating Disorde | 2004 |
Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression.
Topics: Adult; Aged; Antipsychotic Agents; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Diben | 2005 |
Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions.
Topics: Antipsychotic Agents; Anxiety Disorders; Disorders of Excessive Somnolence; Dose-Response Relationsh | 2006 |
Changes in plasma cholesterol in mood disorder patients: does treatment make a difference?
Topics: Acute Disease; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; A | 2007 |
Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Anxiety Disorders; Diagnostic and Statistical Manual o | 2008 |
Atypical antipsychotics for treatment of mixed depression and anxiety.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Comorbidity; Depressive Disorder; D | 2000 |